Telo Genomics Corp. presented the results of its latest study on June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting. This study, executed in conjunction with the Mayo Clinic, was conducted to confirm the utility of the TeloView technology to identify newly diagnosed multiple myeloma (NDMM) patients with a high-risk to relapse within 1 year while receiving first-line therapy.

In this 174-patient study, the TeloView MM assay was used to predict the outcome of patients in 2 cohorts. Cohort 1 exclusively included patients who relapsed within 1 year of initiating first line therapy. Cohort 2 was made up of patients that responded to therapy and had stable disease for over 3 years after starting therapy.

The TeloView MM assay proved to be a powerful predictive tool in both groups, achieving combined accuracy of over 80%. Predicting NDMM patient response to first line therapy is a critical unmet clinical need. In current clinical practice, patients will remain on a specific treatment regimen until relapse and then be switched to an alternative regimen.

The cost of therapy can range between $100,000 - 150,000 per year and most NDMM patients do relapse on first line therapy within 24 months. TeloView-MM testing for the newly diagnosed population has the potential to allow treating physicians to make informed decisions to switch high-risk patients to an alternative treatment proactively and avoid the relapse event. The TeloView-MM assay has the potential to benefit over 35,000 NDMM patients annually in the US with a total addressable market of approximately 300,000 tests per year.